CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa; Paolo F. Caimi; Kirit M. Ardeshna; Melhem Solh; Carmelo Carlo-Stella; Brad S. Kahl; Mehdi Hamadani

doi:10.1182/bloodadvances.2020002587

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S. Kahl, Mehdi Hamadani

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	3850-3852
Number of pages	3
Journal	Blood Advances
Volume	4
Issue number	16
DOIs	https://doi.org/10.1182/bloodadvances.2020002587
State	Published - Aug 25 2020

Access to Document

10.1182/bloodadvances.2020002587

Cite this

@article{df450a88612546fba3c30f53a284d183,

title = "CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy",

author = "Bicky Thapa and Caimi, {Paolo F.} and Ardeshna, {Kirit M.} and Melhem Solh and Carmelo Carlo-Stella and Kahl, {Brad S.} and Mehdi Hamadani",

note = "Funding Information: Acknowledgment: This work is supported by the University College London/University College London Hospitals Biomedical Research Center (K.M.A.). Funding Information: Conflict-of-interest disclosure: M.H. reports research support/ funding from Takeda Pharmaceutical Company and Spectrum Pharmaceuticals; consultancy fees from Incyte Corporation, ADC Therapeutics, Celgene, Pharmacyclics, Omeros, AbGenomics, Verastem, TeneoBio; and serves on speakers bureaus for Sanofi Genzyme and AstraZeneca. P.F.C. reports research support/funding from Genentech; consultancy fees from Genentech, Kite Pharmaceuticals, ADC Therapeutics, Kite Pharmaceuticals, Vera-stem, Amgen, and Bayer; and serves on the speakers bureau for Celgene. C.C.-S. reports research support from ADCT Rhizen Pharmaceuticals; serves as consultant/advisor for Servier, Novartis, Genenta Science srl, ADCT, Roche, Boehringer Ingelheim, and Sanofi; and receives honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Janssen Oncology, and AstraZeneca. The remaining authors declare no competing financial interests.",

year = "2020",

month = aug,

day = "25",

doi = "10.1182/bloodadvances.2020002587",

language = "English",

volume = "4",

pages = "3850--3852",

journal = "Blood Advances",

issn = "2473-9529",

number = "16",

}

TY - JOUR

T1 - CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

AU - Thapa, Bicky

AU - Caimi, Paolo F.

AU - Ardeshna, Kirit M.

AU - Solh, Melhem

AU - Carlo-Stella, Carmelo

AU - Kahl, Brad S.

AU - Hamadani, Mehdi

N1 - Funding Information: Acknowledgment: This work is supported by the University College London/University College London Hospitals Biomedical Research Center (K.M.A.). Funding Information: Conflict-of-interest disclosure: M.H. reports research support/ funding from Takeda Pharmaceutical Company and Spectrum Pharmaceuticals; consultancy fees from Incyte Corporation, ADC Therapeutics, Celgene, Pharmacyclics, Omeros, AbGenomics, Verastem, TeneoBio; and serves on speakers bureaus for Sanofi Genzyme and AstraZeneca. P.F.C. reports research support/funding from Genentech; consultancy fees from Genentech, Kite Pharmaceuticals, ADC Therapeutics, Kite Pharmaceuticals, Vera-stem, Amgen, and Bayer; and serves on the speakers bureau for Celgene. C.C.-S. reports research support from ADCT Rhizen Pharmaceuticals; serves as consultant/advisor for Servier, Novartis, Genenta Science srl, ADCT, Roche, Boehringer Ingelheim, and Sanofi; and receives honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Janssen Oncology, and AstraZeneca. The remaining authors declare no competing financial interests.

PY - 2020/8/25

Y1 - 2020/8/25

UR - http://www.scopus.com/inward/record.url?scp=85096132028&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2020002587

DO - 10.1182/bloodadvances.2020002587

M3 - Article

C2 - 32797191

AN - SCOPUS:85096132028

SN - 2473-9529

VL - 4

SP - 3850

EP - 3852

JO - Blood Advances

JF - Blood Advances

IS - 16

ER -

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Access to Document

Other files and links

Cite this